Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MapLight Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Jonathan Gillis, Chief Financial Officer (Form 8-K filed 2026-06-18). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Nan Fung Group Holdings Limited (filed 2026-08-20).
Who is behind it
MapLight Therapeutics, Inc.: incorporated in Delaware; business address in Redwood City, California; industry Pharmaceutical Preparations (S-1/A, 2026-09-18).
Officers and directors, each with the role and the filing that names them:
- Christopher A Kroeger: Executive Officer, Director (Form D, 2025-07-28)
- George Pavlov: Director (Form D, 2025-07-28)
- Timothy Garnett: Director (Form D, 2025-07-28)
- James Lillie: Executive Officer (Form D, 2025-07-28)
- Peter Bisgaard: Director (Form D, 2025-07-28)
- Jonathan Gillis: Executive Officer (Form D, 2025-07-28)
- Vishwas Setia: Executive Officer (Form D, 2025-07-28)
- Jim Trenkle: Director (Form D, 2025-07-28)
- Maria Walker: Director (Form D, 2025-07-28)
- Kristopher Hanson: Executive Officer (Form D, 2025-07-28)
- Nanna Luneborg: Director (Form D, 2025-07-28)
- Erin Foff: Executive Officer (Form D, 2025-07-28)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-20 | Nan Fung Group Holdings Limited | 5.5% |
| Schedule 13D/A, 2026-08-18 | Catalyst4, Inc. | 49.9% |
| Schedule 13D/A, 2026-08-03 | Catalyst4, Inc. | 47.9% |
| Schedule 13D/A, 2026-07-31 | Novo Holdings A/S | 4.9% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 7.4% |
| Schedule 13G, 2026-02-17 | T. Rowe Price Investment Management, Inc. | 6.2% |
| Schedule 13G, 2026-02-17 | Forbion Growth Opportunities Fund Iii Cooperatief U.A. | 7.1% |
| Schedule 13D, 2025-11-20 | Catalyst4, Inc. | 45.1% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-18 | Jonathan Gillis | Chief Financial Officer | appointed | 2026-06-18 |
| Form 8-K, 2026-04-29 | Robert Malenka | departed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-07-28 | $188.19M | $372.45M |
| Form D, 2023-07-19 | $50M | $175M |
| Form D, 2022-11-10 | $12M | $12M |
Latest IPO step: MapLight Therapeutics, Inc. amended its IPO registration (S-1/A, 2026-09-18).
IPO filings: S-1/A, 2026-09-18, S-1, 2026-09-09, S-1/A, 2025-10-06, S-1, 2025-09-19; ticker MPLT on Nasdaq Global Select Market.
Related pages
Leadership changes5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/maplight-therapeuticsLast updated 2026-10-18
Primary record: Schedule 13G, 2026-08-20 · Form D, 2025-07-28 · Form 8-K, 2026-06-18 · Form 8-K, 2026-04-29
Who owns MapLight Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/maplight-therapeutics